RecruitingNAINTERVENTIONAL

Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer

This study, called ProfiLER, aims to understand advanced cancers better by looking closely at their genetic code and how they interact with the body's immune system. By studying samples of blood and tumour tissue from people with advanced cancer, researchers hope to create a detailed 'map' of different cancer types. This information can help doctors choose more personalised treatments, such as targeted therapies or immunotherapies, which are medicines designed to work specifically against certain cancer features or boost the body's own defence. The goal is to improve how these cancers are managed and potentially find new ways to predict how they might respond to treatment.

At a glance

Status

Recruiting

Phase

Sponsor

Centre Leon Berard

Enrolment target

10,000

Start

01 Feb 2013

Estimated completion

01 Jul 2026

Neoplasms

What is this study about?

This research project, called ProfiLER, is designed to help doctors understand advanced cancers much better so they can offer more personalised treatments. Imagine every cancer as having its own unique 'fingerprint' made up of its genetic code and how it interacts with your body's immune system. This study aims to create a detailed 'map' of these fingerprints for many different advanced cancers.

To do this, doctors will collect small samples of your blood and, if possible, a sample from your tumour. They will then carefully examine these samples to find specific genetic changes and markers related to your immune system. This detailed information will be reviewed by a team of experts who will look for treatment options that are best suited to your cancer's unique profile. This could mean recommending specific targeted medicines or immunotherapies, which are treatments designed to use your own immune system to fight the cancer. These treatments might be ones that are already approved or ones being tested in other clinical trials.

It's important to know that this study isn't directly testing a new drug. Instead, it's about gathering information to help guide your treatment using what we already know or are learning about personalised medicine. By linking the findings from your samples with how your cancer responds to treatment, researchers hope to find new ways to predict which treatments might work best for others in the future and to understand more about how genetic changes in cancer affect the immune system.

Key takeaways

Aims to tailor cancer treatment by understanding your unique tumour.
Involves analysing your blood and tumour samples for genetic and immune markers.
Doctor's team will use the findings to explore the best treatment options.
Does not involve new study drugs; it's about informing existing treatment choices.
Helps researchers learn more about different advanced cancers for the future.

Who may be eligible?

To be able to join this study, you would need to have an advanced cancer that has been confirmed by a doctor. Your cancer could be locally advanced (meaning it has grown into nearby tissues) or metastatic (meaning it has spread to other parts of the body). The type of cancer doesn't matter; it can be any kind.

We need to be able to get a sample of your tumour to study. This could be a sample that was collected in the past and stored, or if possible, a doctor might take a new small sample from a reachable part of your body. This new sample would be taken using a needle, ideally from a tumour that's at least 2cm wide and can be reached safely. Areas like the brain or bones are not considered easily reachable for this purpose.

Also, you need to be receiving treatment for your advanced cancer, either your first, second, or third type of treatment. (Hormone therapy on its own doesn't count as one of these treatments.) If you're over 70, you'd also need to be generally well and able to do most of your usual activities. Finally, you would need to have medical insurance and be able to give your informed consent, or for those under 18, a parent or legal guardian would need to give consent.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Do you have a diagnosis of advanced cancer?
Is there a tumour sample available, or can one be safely taken?
Are you currently receiving your first, second, or third line of treatment for advanced cancer (excluding single-agent hormone therapy)?
Are you able to provide consent to take part?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, the main thing you'll be doing is providing samples of your blood and, if available, a sample from your tumour (either an old sample or a new one taken for the study). We'll also gather information about your health and how your cancer is progressing from your medical records. You won't be given any specific study drugs, and your cancer treatment and follow-up will continue as planned by your usual medical team, possibly with input from the study experts based on your tumour's profile. We don't have a specific end date as this is an observation study, so your participation will continue as long as relevant data can be collected from your medical records.

Potential risks and benefits

A potential benefit of joining this study is that the detailed analysis of your tumour might help your doctors choose a more appropriate and personalised treatment path for your cancer, potentially leading to better outcomes. However, there's no guarantee that participating will directly benefit your health. The main risk, if a new tumour biopsy is taken, is the usual discomfort and small risks associated with any medical procedure, like bruising or a minor infection. You are always free to change your mind and withdraw from the study at any time, for any reason, without it affecting your ongoing medical care.

Locations (6)

Centre Hospitalier Annecy Genevois
Verified postcode
Annecy, France· Recruiting
Groupement Hospitalier Mutualiste
Verified postcode
Grenoble, France· Recruiting
Hôpital Edouard Herriot
Verified postcode
Lyon, France· Not yet recruiting
Centre Léon Bérard
Verified postcode
Lyon, France· Recruiting
Centre Hospitalier Lyon Sud
Verified postcode
Pierre-Bénite, France· Active not recruiting
CHU de Saint-Etienne Hôpital Nord
Verified postcode
Saint-Etienne, France· Recruiting

Common questions

What kind of cancer is this study for?

This study is for people with any type of advanced cancer (either locally advanced or metastatic).

Will I get a new treatment in this study?

No, this study doesn't test new treatments. It gathers information to help your doctors choose the best current treatments for you.

What samples will be taken?

Blood samples will be taken, and either an existing tumour sample will be used, or a new small sample might be taken from your tumour if it's safe to do so.

How long will I be in the study?

There isn't a fixed end date, as the study involves collecting information from your medical records over time to see how different cancers respond.

Will my doctors know the results?

Yes, the detailed report about your cancer's profile will be shared with your medical team to help guide your care.

How to find out more

Jean-Yves BLAY, MD

jean-yves.blay@lyon.unicancer.fr +33 4 78 78 51 26 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.